We are international

Myeloma Minute - October 17, 2004


  • New! Comprehensive Guide to Torino Multiple Myeloma Conference 2004
    Using the 63 presentations given at the conference held in Turin, Italy in April 2004, ten expert faculty members, who participated in this conference, have summarized the presentations and written a comprehensive overview of the meeting’s sessions.

  • IMF to Sponsor Corporate Friday Symposium preceding the 46th American Society of Hematology Annual Meeting
    The CME-certified symposium entitled, “Controversies in Myeloma Management: Diagnosis, Initial Treatment, and the Relapsing Patient” will be jointly sponsored by the IMF and the Institute for Continuing Healthcare Education, an ACCME-accredited provider of continuing medical education.

  • There have been a lot of questions lately from IMFers regarding infusion times for bisphosphonates. One of the major toxicity-related concerns with bisphosphonates relates to kidney side effects. All bisphosphonates are potential toxins for the kidneys. Since myeloma can have an impact on kidney function (due to myeloma protein damage or elevated blood calcium), the possibility of kidney-related side effects is of particular concern. The infusion time for Aredia should be no less than 2 hours, and up to 4 hours, as per the manufacturer’s recommendation. The major concern that has emerged with Zometa is an increase in serum creatinine, which is an indication of kidney dysfunction. In order to avoid an infusion rate that is more rapid than planned or anticipated, an infusion time of 30-45 minutes for Zometa is strongly recommended. Some doctors also follow the infusion with a saline wash to further protect the kidneys. Serum creatinine should be measured monthly within 72 hours before the infusion. Special Advisory on Bisphosphonates and Osteonecrosis of the Jaws

  • A few tickets are still available for the 14th Anniversary Ribbon of Hope Making A World of Difference Gala on November 6 at the Millennium Biltmore Hotel in Los Angeles. Honoring our own Dr. Brian Durie, this promises to be the biggest and best Gala ever. Awards for their dedication to improving the lives of myeloma patients will be given to Karen Talmadge of Kyphon, The Los Angeles MM Support Group, Captain Fred Gloor, and David J. Brown. A beautiful hotel, a gourmet meal, and some of the most awesome auction items ever assembled make for one fabulous night. And the money you pay to have a wonderful time will help the IMF fund its educational and advocacy programs and fund research initiatives. Call 800-452-2873 ext 222 for information.

  • Fighting Myeloma at Sea!
    Read the latest update from Jerry Eisenhower's maritime adventure. Remember, it has been hurricane season in Florida!

  • The Los Angeles Area Multiple Myeloma Support Group
    will meet on October 23, not their usual meeting time. Their speaker will be Ferre Akbarpour, M.D., speaking on Multiple Myeloma and the Immune System.  As the medical director of the Orange County Immune Institute, Dr. Ferre enables her patients to promote healing through an understanding of how the biochemistry and genetics of cancer cells differ from normal cells. For more information, call Sheila Wilson at 323.876.1288.


    • VELCADE® trials
    • THALOMID® trials
    • TRISENOX™ trials UPDATED 10/14
    • REVLIMID trials

    • Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for non-Responders       
      Eastern Cooperative Oncology Group E4A03
      Opens October 22, 2004

    • Researchers will shortly be enrolling newly diagnosed myeloma patients in a randomized, multi-center, Phase III clinical trial entitled “Thal/Dex (Thalidomide and Dexamethasone) vs. Dvd-T (Doxil, Vincristine, Dexamethasone and Thalidomide) in newly diagnosed multiple myeloma patients.”  Tibotec, a subsidiary of Ortho Biotech, is sponsoring the research.  We will keep you posted as the sites open for enrollment.


For more information, the Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.



If you live near any these local fundraisers, why not go on over? They are always fun, and the money raised helps the IMF help others.

FUNdraising Made Easy
Suzanne Battaglia can help you plan your fundraiser, so please write, call or email (SBattaglia@myeloma.org) so that you can get on our Calendar of Events!




Many of the internet's most popular merchants will donate a portion of your purchases to the IMF if you enter their sites using the links on our Shop For The IMF page. So, Be Part of the Cure by using these links to get the same great service and low prices you're used to while helping support the IMF!

Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Tax-deductible donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.

Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.

 related articles